4/A//SEC Filing
ARSENAULT KAITLYN 4/A
Accession 0001516551-25-000022
CIK 0001516551other
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 6:54 PM ET
Size
7.6 KB
Accession
0001516551-25-000022
Insider Transaction Report
Form 4/AAmended
ARSENAULT KAITLYN
Chief Financial Officer
Transactions
- Sale
Common Stock
2024-11-18$4.99/sh−43,026$214,700→ 167,522 total - Sale
Common Stock
2024-11-15$5.55/sh−190$1,055→ 210,548 total
Footnotes (2)
- [F1]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person.
- [F2]The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.
Documents
Issuer
Skye Bioscience, Inc.
CIK 0001516551
Entity typeother
Related Parties
1- filerCIK 0001877242
Filing Metadata
- Form type
- 4/A
- Filed
- Feb 27, 7:00 PM ET
- Accepted
- Feb 28, 6:54 PM ET
- Size
- 7.6 KB